Literature DB >> 29362866

[Kit-based radiolabeling of PSMA ligands].

T Derlin1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29362866     DOI： 10.1007/s00117-018-0362-z

Source DB:  PubMed          Journal:  Radiologe        ISSN： 0033-832X            Impact factor:   0.635


× No keyword cloud information.
  4 in total

1.  Comparison of standard and delayed imaging to improve the detection rate of [68Ga]PSMA I&T PET/CT in patients with biochemical recurrence or prostate-specific antigen persistence after primary therapy for prostate cancer.

Authors:  Sebastian Schmuck; Stefan Nordlohne; Christoph-A von Klot; Christoph Henkenberens; Jan M Sohns; Hans Christiansen; Hans-Jürgen Wester; Tobias L Ross; Frank M Bengel; Thorsten Derlin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-03-09       Impact factor: 9.236

2.  Initial Experience with Volumetric 68Ga-PSMA I&T PET/CT for Assessment of Whole-Body Tumor Burden as a Quantitative Imaging Biomarker in Patients with Prostate Cancer.

Authors:  Sebastian Schmuck; Christoph A von Klot; Christoph Henkenberens; Jan M Sohns; Hans Christiansen; Hans-Jürgen Wester; Tobias L Ross; Frank M Bengel; Thorsten Derlin
Journal:  J Nucl Med       Date:  2017-05-18       Impact factor: 10.057

3.  68Ga-THP-PSMA: A PET Imaging Agent for Prostate Cancer Offering Rapid, Room-Temperature, 1-Step Kit-Based Radiolabeling.

Authors:  Jennifer D Young; Vincenzo Abbate; Cinzia Imberti; Levente K Meszaros; Michelle T Ma; Samantha Y A Terry; Robert C Hider; Greg E Mullen; Philip J Blower
Journal:  J Nucl Med       Date:  2017-04-13       Impact factor: 10.057

Review 4.  Patient experience in the treatment of metastatic castration-resistant prostate cancer: state of the science.

Authors:  N Nussbaum; D J George; A P Abernethy; C M Dolan; N Oestreicher; S Flanders; T B Dorff
Journal:  Prostate Cancer Prostatic Dis       Date:  2016-02-02       Impact factor: 5.554
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.